Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 18, pg 904, 2017)

被引：0
|
作者：
Baselga, J.
Im, S-A
Iwata, H.
机构：
来源：
LANCET ONCOLOGY | 2019年 / 20卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E71 / E72
页数：2
相关论文
共 50 条
  • [1] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Baselga, Jose
    Im, Seock-Ah
    Iwata, Hiroji
    Cortes, Javier
    De laurentiis, Michele
    Jiang, Zefei
    Arteaga, Carlos L.
    Jonat, Walter
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Takahashi, Masato
    Vuylsteke, Peter
    Hachemi, Soulef
    Dharan, Bharani
    Di Tomaso, Emmanuelle
    Urban, Patrick
    Massacesi, Cristian
    Campone, Mario
    LANCET ONCOLOGY, 2017, 18 (07): : 904 - 916
  • [2] Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Di Leo, Angelo
    Johnston, Stephen
    Lee, Keun Seok
    Ciruelos, Eva
    Lonning, Per E.
    Janni, Wolfgang
    O'Regan, Ruth
    Mouret-Reynier, Marie-Ange
    Kalev, Dimitar
    Egle, Daniel
    Csoszi, Tibor
    Bordonaro, Roberto
    Decker, Thomas
    Tjan-Heijnen, Vivianne C. G.
    Blau, Sibel
    Schirone, Alessio
    Weber, Denis
    El-Hashimy, Mona
    Dharan, Bharani
    Sellami, Dalila
    Bachelot, Thomas
    LANCET ONCOLOGY, 2018, 19 (01): : 87 - 100
  • [3] Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
    Campone, Mario
    Im, Seock-Ah
    Iwata, Hiroji
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Cortes, Javier
    De Laurentiis, Michele
    Arteaga, Carlos L.
    Jiang, Zefei
    Jonat, Walter
    Le Mouhaer, Sylvie
    Sankaran, Banu
    Bourdeau, Laurence
    El-Hashimy, Mona
    Sellami, Dalila
    Baselga, Jose
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : 147 - 154
  • [4] Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
    Binghe Xu
    Qingyuan Zhang
    Pin Zhang
    Xichun Hu
    Wei Li
    Zhongsheng Tong
    Tao Sun
    Yuee Teng
    Xinhong Wu
    Quchang Ouyang
    Xi Yan
    Jing Cheng
    Qiang Liu
    Jifeng Feng
    Xiaojia Wang
    Yongmei Yin
    Yanxia Shi
    Yueyin Pan
    Yongsheng Wang
    Weimin Xie
    Min Yan
    Yunjiang Liu
    Ping Yan
    Fei Wu
    Xiaoyu Zhu
    Jianjun Zou
    Nature Medicine, 2021, 27 : 1904 - 1909
  • [5] Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
    Xu, Binghe
    Zhang, Qingyuan
    Zhang, Pin
    Hu, Xichun
    Li, Wei
    Tong, Zhongsheng
    Sun, Tao
    Teng, Yuee
    Wu, Xinhong
    Ouyang, Quchang
    Yan, Xi
    Cheng, Jing
    Liu, Qiang
    Feng, Jifeng
    Wang, Xiaojia
    Yin, Yongmei
    Shi, Yanxia
    Pan, Yueyin
    Wang, Yongsheng
    Xie, Weimin
    Yan, Min
    Liu, Yunjiang
    Yan, Ping
    Wu, Fei
    Zhu, Xiaoyu
    Zou, Jianjun
    NATURE MEDICINE, 2021, 27 (11) : 1904 - +
  • [6] Capivasertib plus fulvestrant versus placebo plus fulvestrant in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial
    Jones, Robert
    Carucci, Margherita
    Casbard, Angela
    Butler, Rachel
    Bale, Catherine
    Alchami, Fouad
    Bezecny, Pavel
    Joffe, Johnathan
    Moon, Sarah
    Twelves, Chris
    Venkitaraman, Ramachandran
    Waters, Simon
    Howell, Sacha
    BRITISH JOURNAL OF CANCER, 2019, 121 : 19 - 19
  • [7] Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
    Liu, Qi
    Hou, Lingli
    Zhao, Ying
    Yang, Hongwei
    Mo, Zhengying
    Yu, Fei
    CLINICS, 2023, 78
  • [8] Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, doubleblind, placebo-controlled, phase 3 trial (vol 19, pg 87, 2018)
    Di Leo, A.
    Johnston, S.
    Lee, K. S.
    LANCET ONCOLOGY, 2018, 19 (03): : E137 - E137
  • [9] Fulvestrant plus capivasertib versus placebo in metastatic ER positive breast cancer (FAKTION): a randomised, double-blind, placebo-controlled, phase II trial
    Howell, Sacha Jon
    Carucci, Margherita
    Casbard, Angela
    Cox, Catrin
    Butler, Rachel
    Alchami, Fouad
    Bale, Catherine
    Bezecny, Pavel
    Joffe, Johnathan
    Moon, Sarah
    Twelves, Chris
    Venkitaraman, Ramachadran
    Waters, Simon
    Jones, Robert Hugh
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 530 - 531
  • [10] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
    Cristofanilli, Massimo
    Turner, Nicholas C.
    Bondarenko, Igor
    Ro, Jungsil
    Im, Seock-Ah
    Masuda, Norikazu
    Colleoni, Marco
    DeMichele, Angela
    Loi, Sherene
    Verma, Sunil
    Iwata, Hiroji
    Harbeck, Nadia
    Zhang, Ke
    Theall, Kathy Puyana
    Jiang, Yuqiu
    Bartlett, Cynthia Huang
    Koehler, Maria
    Slamon, Dennis
    LANCET ONCOLOGY, 2016, 17 (04): : 425 - 439
12345